Disease Domain | Count |
---|---|
Neoplasms | 3 |
Endocrinology and Metabolic Disease | 3 |
Nervous System Diseases | 2 |
Hemic and Lymphatic Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 5 |
Recombinant protein | 1 |
Target |
Mechanism Molybdenum cofactor stimulants |
Active Org. ![]() |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date26 Feb 2021 |
Mechanism FGFR1 antagonists [+3] |
Originator Org. ![]() |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc. US |
First Approval Date28 May 2021 |
Target |
Mechanism COL7A1 modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date10 Nov 2023 |
Sponsor / Collaborator ![]() |
Start Date12 Jul 2023 |
Sponsor / Collaborator ![]() [+2] |
Start Date20 Oct 2022 |
Sponsor / Collaborator ![]() [+1] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Fosdenopterin ( Molybdenum cofactor ) | Molybdenum Cofactor Deficiency, Complementation Group A More | Phase 3 |
Infigratinib ( FGFR1 x FGFR2 x FGFR3 x FGFR4 ) | Transitional Cell Carcinoma More | Phase 3 |
PTR-01 ( COL7A1 ) | Epidermolysis Bullosa More | Phase 2 |
VT-30 ( PI3Kα ) | Vascular Malformations More | Phase 2 |
BBP-398 ( SHP2 ) | KRAS G12C mutation Solid Tumors More | Phase 1 |